Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70051 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Cita Rosita Sigit Prakoeswa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Aesthetic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Urea, Emollients, Skin Cream. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: La Roche-Posay Laboratoire Dermatologique.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) poses a challenge due to its chronic inflammatory nature. Recent research highlights microbiome dysbiosis as a key contributor. Emollients “plus” are modern moisturizers containing bacterial lysate, improving skin barrier function and reducing Staphylococcus aureus colonization, thus mitigating AD symptoms. Emollient “plus” containing Vitreoscilla filiformis biomass ( Aqua Posae filiformis ) is efficient in AD, as single adjunct for milder forms or adjunctive to systemic treatments in more severe forms. Standard recommended moisturizers for AD in Indonesia contain urea 10%.
Aims
This trial compared an emollient “plus” (Group A) with urea 10% moisturizer (Group B) in the treatment of mild‐to‐moderate AD. Patients/Methods Sixty subjects with mild‐to‐moderate AD were randomized into Groups A and B (30 subjects/group). Test products were applied twice daily for 12 weeks. Clinical and instrumental endpoints assessed at Weeks 0, 4, 8, and 12 included Severity Scoring of AD (SCORAD), Pruritus Visual Analog Scale (PVAS), Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), Transepidermal Water Loss (TEWL), skin hydration, skin pH, as well as tolerance evaluation.
Results
Significant differences in favor of the emollient “plus” versus urea 10% were observed on TEWL and skin pH values at Weeks 4, 8, and 12, on SCORAD and skin hydration values at Weeks 8 and 12. EASI, DLQI, and PVAS values differed significantly at Week 12 in favor of Group A. Both products were well tolerated.
Conclusions
This emollient “plus” has superior efficacy in improving AD symptoms and skin barrier function compared to urea 10% moisturizer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Venereology and Aesthetic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
- Department of Dermatology, Venereology and Aesthetic, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.
- La Roche-Posay Laboratoire Dermatologique, Levallois Perret, France.
ORCID-Profile: Delphine Kerob
Förderung
- La Roche-Posay Laboratoire Dermatologique
Zitieren
APA
Prakoeswa, C. R. S., Huda, B. K. N., Indrawati, D., Umborowati, M. A., Anggraeni, S., Damayanti, Murtiastutik, D., & Kerob, D. (2025). Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70051
Vancouver
Prakoeswa CRS, Huda BKN, Indrawati D, Umborowati MA, Anggraeni S, Damayanti, et al. Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70051
BibTeX
@article{Prakoeswa2025,
author = {Prakoeswa, Cita Rosita Sigit and Huda, Berliana Kurniawati Nur and Indrawati, Ditya and Umborowati, Menul Ayu and Anggraeni, Sylvia and Damayanti and Murtiastutik, Dwi and Kerob, Delphine},
title = {Effectiveness and Tolerability of an Emollient “Plus” Compared to Urea 10% in Patients With Mild‐to‐Moderate Atopic Dermatitis},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70051}
}
EUVIMED